CN101569302A - In-vitro liver perfusion preservation liquid - Google Patents
In-vitro liver perfusion preservation liquid Download PDFInfo
- Publication number
- CN101569302A CN101569302A CNA200810036928XA CN200810036928A CN101569302A CN 101569302 A CN101569302 A CN 101569302A CN A200810036928X A CNA200810036928X A CN A200810036928XA CN 200810036928 A CN200810036928 A CN 200810036928A CN 101569302 A CN101569302 A CN 101569302A
- Authority
- CN
- China
- Prior art keywords
- liquid
- adenosine
- liter
- graft
- preservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 27
- 238000004321 preservation Methods 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 title claims description 63
- 230000010412 perfusion Effects 0.000 title abstract description 8
- 238000000338 in vitro Methods 0.000 title abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 27
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 22
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims abstract description 14
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 13
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 13
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- 229960005305 adenosine Drugs 0.000 claims abstract description 12
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 229960001722 verapamil Drugs 0.000 claims abstract description 12
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 11
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 11
- 108010024636 Glutathione Proteins 0.000 claims abstract description 11
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960003459 allopurinol Drugs 0.000 claims abstract description 11
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 11
- 229960003178 choline chloride Drugs 0.000 claims abstract description 11
- 229960003180 glutathione Drugs 0.000 claims abstract description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 10
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 22
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 20
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 16
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 11
- 229940055726 pantothenic acid Drugs 0.000 claims description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims description 11
- 239000011713 pantothenic acid Substances 0.000 claims description 11
- 229960003581 pyridoxal Drugs 0.000 claims description 11
- 235000008164 pyridoxal Nutrition 0.000 claims description 11
- 239000011674 pyridoxal Substances 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 10
- 235000019766 L-Lysine Nutrition 0.000 claims description 10
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 10
- 229930064664 L-arginine Natural products 0.000 claims description 10
- 235000014852 L-arginine Nutrition 0.000 claims description 10
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 10
- 239000004158 L-cystine Substances 0.000 claims description 10
- 235000019393 L-cystine Nutrition 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 10
- 229930182844 L-isoleucine Natural products 0.000 claims description 10
- 235000019454 L-leucine Nutrition 0.000 claims description 10
- 239000004395 L-leucine Substances 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- 229930195722 L-methionine Natural products 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 10
- 239000004473 Threonine Substances 0.000 claims description 10
- 229960003067 cystine Drugs 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 10
- 229960003136 leucine Drugs 0.000 claims description 10
- 229960004452 methionine Drugs 0.000 claims description 10
- 229960001153 serine Drugs 0.000 claims description 10
- 229960002898 threonine Drugs 0.000 claims description 10
- 229960004799 tryptophan Drugs 0.000 claims description 10
- 229960004295 valine Drugs 0.000 claims description 10
- 239000011708 vitamin B3 Substances 0.000 claims description 10
- 235000019160 vitamin B3 Nutrition 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 229960004441 tyrosine Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229940084971 dexamethasone 6 mg Drugs 0.000 claims 2
- 229940019142 folic acid 5 mg Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 7
- 239000001301 oxygen Substances 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 230000004083 survival effect Effects 0.000 abstract description 7
- 206010030113 Oedema Diseases 0.000 abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 208000024908 graft versus host disease Diseases 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 229960001456 adenosine triphosphate Drugs 0.000 abstract description 2
- 229940024606 amino acid Drugs 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 239000003792 electrolyte Substances 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 239000003761 preservation solution Substances 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 229940037395 electrolytes Drugs 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 abstract 1
- 235000001727 glucose Nutrition 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 229950008558 ulinastatin Drugs 0.000 abstract 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010088854 urinastatin Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 7
- 229950006790 adenosine phosphate Drugs 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108700027941 Celsior Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002016 colloidosmotic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an in vitro liver perfusion preservation solution, which contains various electrolytes, amino acids, vitamins, choline chloride, glucose, adenosine triphosphate, adenosine, plasma albumin, low molecular dextran, erythrocytes, verapamil, dexamethasone, glutathione, allopurinol, ulinastatin, soluble TNF-alpha, soluble IL-I and other components. The preservation solution can provide sufficient oxygen and sufficient energy supply, can be effectively applied to preservation of in vitro liver at 0-4 ℃, and has the characteristics of low production cost, proper viscosity, long perfusion preservation time, small damage to liver and few complications; can also prevent ischemic injury, cell edema and secondary injury caused by low temperature, and improve the survival rate of the graft in the host; in addition, the host-versus-graft and graft-versus-host reactions during organ transplantation can be effectively reduced, and the survival time of the graft can be prolonged.
Description
Technical field
The present invention relates to a kind of isolated organ perfusion and preserve liquid, relate in particular to a kind of preservative fluid for perfusing extracorporeal liver.
Background technology
Present treat transplant organ preserve liquid the most frequently used be that UW liquid, HTK preserve liquid, Celsior preserves liquid etc.; the application of two kinds of preservation liquid in spare-part surgery is comparatively extensive before outstanding; these preservation liquid have advantage separately; can protect transplant organ largely; but their preparation cost is higher, expense is expensive; be not easy to transportation, store and use, and the complication of initiation internal organs is quite a few.There is following shortcoming in the liquid of clinical discovery UW preservation at present: cause that higher ischemic type biliary tract damages incidence; Contain the high molecular weight components HES, high viscosity, can not fully pour into each sinus hepaticus, the shortcoming that causes disturbance of circulation also therefore to influence transplanting back graft function .HTK preservation liquid is and UW preserves the liquid phase ratio, if the holding time surpasses 10h, former the non-functional incidence of graft can raise significantly.The clinical application effect that Celsior preserves liquid also needs further research.And biliary complications and liver microcirculation disorders these liquid often are recurrent in perfusion and preservation internal organs.
In addition, in liver transplant, also have a lot of tree-removers can since the holding time restriction lose, even transfer operation is very successful, but because the preservation process causes decline of liver quality and immunological rejection to cause graft failure to the damage of hepatic tissue.Reason that holding time is short and present simple stored refrigerated mode, preservation liquid composition and perfusion situation have direct relation.The characteristics of simple refrigeration are by providing low temperature environment (0～4 ℃) to reduce the organ metabolic rate, and adopt the preservation liquid of hyperosmosis to prevent the hepatic tissue oedema.
Summary of the invention
The technical issues that need to address of the present invention provide a kind of new preservative fluid for perfusing extracorporeal liver, thereby can more fully provide oxygen and energy for liver organization, minimizing is to the infringement of liver, prevent ischemia injury, edema and secondary injury thereof that low temperature causes, improve the survival rate of graft in the host, prolong the time-to-live of graft.
In order to solve the problems of the technologies described above, the present invention is achieved by the following technical solutions:
A kind of preservative fluid for perfusing extracorporeal liver is preserved each component that can contain following content in the liquid for every liter: NaCl 4～8g, KCl 0.1～0.8g, NaH
2PO
4H
2O 20～300mg, MgSO
410～200mg, NaHCO
32～9g, L-arginine 50～200mg, histidine 15～120mg, L-cystine 25～140mg, L-methionine 5～100mg, l-glutamine 250～1000mg, L-lysine 50～300mg, glycine 5～100mg, L-isoleucine 35～300mg, L-serine 15～100mg, L-leucine 35～300mg, L-tryptophan 5～40mg, L-trorsine 14 0～300mg, L-valine 35～300mg, L-threonine 40～300mg, Choline Chloride 1～16mg, Cobastab
20.3～6mg, pantothenic acid 1～16mg, folic acid 1～16mg, pyridoxal 1～20mg, vitamin PP 1～20mg, glucose 0.5～20g, ATP (adenosine triphosphate) 0.1～10g, adenosine 0.5～20g, plasma albumin 5～100g, D-40 5～100g, red blood cell 0.5～300g, Verapamil 0.5～10mg, dexamethasone 2～20mg, glutathione 2～20mg, allopurinol 2～20mg, UTI 25,000～50,000u/kg, and be added into 1 liter of deionized water of preserving liquid measure.
Preferably, the present invention preserves each component that can contain following content in the liquid for every liter: NaCl5.0～7.0g, KCl 0.3～0.5g, NaH
2PO
4H
2O 100～150mg, MgSO
450～100mg, NaHCO
34.0～5.0g, L-arginine 80～90mg, histidine 40～60mg, L-cystine 50～70mg, L-methionine 30～50mg, l-glutamine 600～800mg, L-lysine 100～200mg, glycine 20～50mg, L-isoleucine 70～100mg, L-serine 40～100mg, L-leucine 80～150mg, L-tryptophan 10～20mg, L-tyrosine 80～150mg, L-valine 80～150mg, L-threonine 100～200mg, Choline Chloride 2～8mg, Cobastab
20.5～2.5mg, pantothenic acid 2～8mg, folic acid 3～10mg, pyridoxal 3～10mg, vitamin PP 5～10mg, glucose 4～10g, ATP (adenosine triphosphate) 3～5g, adenosine 2～10g, plasma albumin 20～50g, Dextran-20～50g, red blood cell 50～100g, Verapamil 1～5mg, dexamethasone 4～10mg, glutathione 4～10mg, allopurinol 4～10mg and UTI 25,000～40,000u/kg.
More preferably, the present invention preserves each component that can contain following content in the liquid for every liter: NaCl5.3～6.3g, KCl 0.31～0.50g, NaH
2PO
4H
2O 110～145mg, MgSO
458～80mg, NaHCO
34.1～4.9g, L-arginine 81～85mg, histidine 48～58mg, L-cystine 51～65mg, L-methionine 34～47mg, l-glutamine 612～700mg, L-lysine 112～154mg, glycine 28～43m g, L-isoleucine 71～92mg, L-serine 41～91mg, L-leucine 82～131mg, L-tryptophan 13～19mg, L-tyrosine 85～143mg, L-valine 86～125mg, L-threonine 133～159mg, Choline Chloride 3～5mg, Cobastab
20.9～2.3mg, pantothenic acid 3～4mg, folic acid 4～9mg, pyridoxal 4～9mg, vitamin PP 7～8mg, glucose 4.6～9.9g, ATP (adenosine triphosphate) 3.4～4.9g, adenosine 3～9g, plasma albumin 24～48g, D-40 28～43g, red blood cell 57～71g, Verapamil 1～5mg, dexamethasone 6～7mg, glutathione 6～7mg, allopurinol 4～9mg and UTI 25,000～40,000u/kg.
Preferably, can also add soluble TNF-α 30-300ug/L and/or solubility IL-I 30-300ug/L in the above-mentioned preservative fluid for perfusing extracorporeal liver of the present invention with HVG or graft-versus-host reaction in the middle of the reduction organ transplant process, thereby improve the graft survival rate.
It is to preserve on the basis of liquid, Celsior preservation formula of liquid at multianalysis UW liquid, HTK that the present invention preserves liquid, new development in conjunction with Organ Preservation, simplify the composition of having improved above-mentioned preservation liquid, through formulated repeatedly, it is as follows to compare improvements and be the content and the role that add each component materials:
1, main improvements
(1) with UW liquid phase ratio, do not adopt kapok sugar and HES etc. to increase the composition of liquid viscosity, thereby reduced residual in biliary tract and blood vessel of preservation liquid effectively, avoided causing thus to the infringement of liver organization and the generation of complication.
(2) this pH value (7.35), osmotic concentration (350mosm/L) of preserving liquid is comparatively suitable, (the pH value is 7.4 than UW liquid, osmotic concentration is 350mosm/L), HTK preserves liquid (the pH value is 7.2, osmotic concentration is 310mosm/L), Celsior preserves the easier incidence that reduces the liver cell oedema of liquid (pH value is 7.3, and osmotic concentration is 320mosm/L).
(3) add soluble TNF-α 30-300ug/L and/or solubility IL-I 30-300ug/L and can reduce central HVG of organ transplant process or graft-versus-host reaction, thereby improve the graft survival rate.
2, other improvements:
(1) plasma albumin can be kept colloid osmotic pressure; D-40 can improve CBF, reach to keep the plasma colloid osmotic pressure purpose, and it has better action to microcirculation, and platelet aggregation is also eliminated in prevention, helps pouring into again.
(2) adding erythrocytic purpose is to increase to take oxygen, guarantees effective oxygen carrying content of perfusion preservation liquid; Add energy matter,, fully guarantee the supply of stripped liver utilizable energy quantity of material as glucose, ATP, adenosine etc.; Vitamin b3 (Cobastab
2), vitamin substances such as folic acid, pyridoxal, pantothenic acid, can give the required coenzyme of analytic metabolism etc.
(3) Verapamil is a calcium antagonist, can alleviate calcium overload, protective wire plastochondria, reduce the oxygen radical generation, and in addition, it still has the effect that suppresses platelet aggregation; Dexamethasone is a membrane stabilizer, has the membrane stability effect.
(4) UTI can play the effect that suppresses the histocyte metabolism, makes the organ that is saved reduce metabolic enzyme under the normal temperature storage temperature, reduces katabolism, prolongs histocyte life.
Preservative fluid for perfusing extracorporeal liver of the present invention is the same with existing preservation liquid to be applicable to 0～4 ℃ of low temperature environment, compared with prior art, the invention has the beneficial effects as follows: not only can provide sufficient oxygen, and can provide sufficient energy to supply with, thereby the low temperature that can be effectively applied to stripped liver is preserved, it is low to have production cost, low viscosity, holding time is longer, little and the few characteristics of complication to liver damage, can effectively reduce HVG and graft-versus-host reaction in the organ transplant process, prolong the time-to-live of graft, improve the survival rate of graft in the host, in addition, can also prevent the ischemia injury that low temperature causes, edema and secondary injury thereof.
Description of drawings
Fig. 1 is that the Pathomorphology of three groups of hepatic tissues phase when 40h changes (HE * 400), and wherein A: embodiment is 2 groups, B:UW liquid group, C:HTK liquid group.
Embodiment
Further specify the present invention with embodiment below, but the present invention is not limited.
Each component materials can both be on sale on market in the following example.
Below the total amount of preservation liquid of every example be 1 liter:
| Composition | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| NaCl(g) | 5.3 | 6.3 | 5.3 |
| KCl(mg) | 310 | 450 | 500 |
| NaH 2PO 4·H 2O(mg) | 110 | 145 | 127 |
| MgSO 4(mg) | 68 | 58 | 80 |
| NaHCO 3(g) | 4.1 | 4.9 | 4.4 |
| L-arginine (mg) | 82 | 81 | 85 |
| Histidine (mg) | 49 | 48 | 58 |
| L-cystine (mg) | 51 | 63 | 65 |
| L-methionine (mg) | 47 | 34 | 39 |
| L-glutamine (mg) | 700 | 689 | 612 |
| L-lysine (mg) | 112 | 154 | 151 |
| Glycine (mg) | 43 | 42 | 28 |
| L-isoleucine (mg) | 71 | 92 | 89 |
| L-serine (mg) | 41 | 43 | 91 |
| L-leucine (mg) | 131 | 91 | 82 |
| L-tryptophan (mg) | 13 | 17 | 19 |
| L-tyrosine (mg) | 143 | 85 | 98 |
| L-valine (rag) | 86 | 125 | 97 |
| L-threonine (mg) | 133 | 135 | 159 |
| Choline Chloride (mg) | 5 | 3 | 3 |
| Cobastab 2(mg) | 2.3 | 1.8 | 0.9 |
| Pantothenic acid (mg) | 4 | 3 | 4 |
| Folic acid (mg) | 4 | 9 | 5 |
| Pyridoxal (mg) | 4 | 5 | 9 |
| Vitamin PP (mg) | 8 | 7 | 7 |
| Glucose (mg) | 9500 | 9900 | 4600 |
| ATP(g) | 4.9 | 3.4 | 4.8 |
| Adenosine (g) | 9 | 3 | 5 |
| Plasma albumin (g) | 46 | 24 | 48 |
| D-40 (g) | 28 | 43 | 32 |
| Red blood cell (g) | 71 | 65 | 57 |
| Verapamil (mg) | 3 | 5 | 1 |
| Dexamethasone (mg) | 6 | 6 | 7 |
| Glutathione (mg) | 6 | 7 | 6 |
| Allopurinol (mg) | 4 | 9 | 7 |
| TNF-α(ug/L) | 30 | 200 | 300 |
| IL-I(ug/L) | 30 | 200 | 300 |
| UTI (u/kg) | 25000 | 30000 | 40000 |
| Deionized water | Be added into 1 liter | Be added into 1 liter | Be added into 1 liter |
Compound method of the present invention: get the part deionized water, with electrolyte (NaCl, KCl, NaH
2PO
4H
2O, MgSO
4, NaHCO
3) at first add wherein, add compositions such as each seed amino acid and plasma albumin then, add red blood cell at last, be settled to 1 liter of total amount with deionized water again.
Experimental example 1
1, main material and reagent: laboratory animal is 90 of adult healthy male and female SD rats, about 300g, is divided into embodiment 2 (patent liquid) group, UW liquid group and HTK group at random.Every group is further divided into 3 groups (n=6) according to the holding time (8h, 16h, 24h, 32h, 40h).Main agents is adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenylate (AMP) sodium salt, Proteinase K, UW liquid and HTK liquid and TUNEL method Apoptosis kit etc.
2, method: it is mainly according to list of references [Xu Dongbo that the stripped liver of (1) rat low temperature continues perfusion preservation Preparation of model, Du Zhi, Potts D J, Deng. the foundation of isolated rat liver re-perfusion model (IPRI) and the meaning [J] in the experiment of liver transfer operation organ preservative fluid thereof. biomedical engineering and clinical, 2001,5:1-3.] the biological isolated rat liver re-perfusion model (IPRI) introduced carries out.(2) mensuration of stripped liver organization energy matter: mainly according to list of references [Zhou Zhihua, Cui Xingang, Han Qiucheng, Deng. the how dirty organ preservative fluid in Shanghai is preserved the experimental study [J] of isolated rat liver. the The 2nd Army Medical College journal, 2007,28 (2): 122-126.] the quick isoconcentration high-efficient liquid phase chromatogram technology of introducing detects the content of ATP, ADP, AMP in the different holding time hepatic tissues, and calculates adenosine phosphate total amount TAN=ATP+ADP+AMP.(3) light microscopic is observed the hepatic tissue morphological change that exsomatizes down.(4) the TUNEL method detects the Apoptosis change.(5) statistical procedures: SPSS 11.0 softwares carry out data statistic analysis, and continuous data is represented with x ± s, relatively adopts Student t check between group, and P＜0.05 is variant for statistics.
3, result: put when five of 8h, 16h, 24h, 32h, 40h mutually (1), and each content and adenosine phosphate total amount of organizing ATP, ADP, AMP all reduces, but each content in embodiment 2 (patent liquid) group sees Table 1 apparently higher than other two groups (P＜0.05).(2) om observation result: the liver cell morphology that each group goes up when 8h, 16h mutually is all normal substantially; When 24h, 32h, go up mutually and cellular swelling, steatosis, the visible a spot of neutrophil infiltration in portal area just occur, endochylema is loose, the balloon sample becomes, and visible a small amount of sinusoidal endothelial cell is shed in the sinus hepaticus chamber slight inflammatory reactions such as the generation of no necrosis of liver cells; Mutually above-mentioned inflammation slightly increases the weight of when 40h, the visible neutrophil infiltration in portal area, and the change of liver cell cavity shape, acidophilia or spotty necrosis, but embodiment 2 (patent liquid) group is compared other two groups of inflammation changes light (as Fig. 1).(3) each group is preserved the testing result of liquid to hepatocellular apoptosis; More than in three groups liver cell 8h, 16h, 24h, 32h, 40h each the time all can see the phenomenon of apoptosis mutually, and along with the continuous prolongation of pouring into the holding time, apoptotic cells liquid increases gradually, especially go up more obviously when 32h, 40h mutually, but wherein hepatocellular apoptosis quantity is that embodiment 2 (patent liquid) group is minimum, and HTK liquid group is maximum, UW is mediate, P＜0.05, showing has significant difference, sees Table 2.
Table 1 liver tissues of rats is preserved in the liquid not simultaneously the energy matter content of phase (μ mol/g, n=6, x ± s) at three kinds
Three kinds in table 2 is preserved liquid at the not influence of liver cell apoptotic index relatively simultaneously (n=6, x ± s)
The above results shows, embodiment 2 groups (patent liquid) obviously is better than UW liquid group and HTK liquid group to the effect of isolated rat hepatic energy metabolism, morphosis and hepatocellular apoptosis.
So, the present invention not only can provide sufficient oxygen, and can provide sufficient Power supply, thereby the low temperature that can be effectively applied to stripped liver is preserved, have that production cost is low, viscosity suitably, continue the characteristics of long, little to liver damage and few intercurrent disease of holding time, can effectively reduce HVG and graft-versus-host reaction in the organ migration process, prolong the time-to-live of graft, improve the survival rate of graft in the host, in addition, can also prevent ischemia injury, edema and the secondary injury thereof that low temperature causes. The present invention is not limited only to liver transplant and preserves, and also can be used for the preservation of other organ, tissue and cells of living such as pancreas, kidney.
Claims (7)
1, a kind of preservative fluid for perfusing extracorporeal liver is preserved each component that contains following content in the liquid for every liter: NaCl 4～8g, KCl 0.1～0.8g, NaH
2PO
4H
2O 20～300mg, MgSO
410～200mg, NaHCO
32～9g, L-arginine 50～200mg, histidine 15～120mg, L-cystine 25～140mg, L-methionine 5～100mg, l-glutamine 250～1000mg, L-lysine 50～300mg, glycine 5～100mg, L-isoleucine 35～300mg, L-serine 15～100mg, L-leucine 35～300mg, L-tryptophan 5～40mg, L-trorsine 14 0～300mg, L-valine 35～300mg, L-threonine 40～300mg, Choline Chloride 1～16mg, Cobastab
20.3～6mg, pantothenic acid 1～16mg, folic acid 1～16mg, pyridoxal 1～20mg, vitamin PP 1～20mg, glucose 0.5～20g, adenosine triphosphate 0.1～10g, adenosine 0.5～20g, plasma albumin 5～100g, D-40 5～100g, red blood cell 0.5～300g, Verapamil 0.5～10mg, dexamethasone 2～20mg, glutathione 2～20mg, allopurinol 2～20mg, UTI 25,000～50,000u/kg, and be added into 1 liter of deionized water of preserving liquid measure.
2, preservation liquid as claimed in claim 1 is characterized in that every liter is preserved each component that contains following content in the liquid: NaCl 5.0～7.0g, KCl 0.3～0.5g, NaH
2PO
4H
2O 100～150mg, MgSO
450～100mg, NaHCO
34.0～5.0g, L-arginine 80～90mg, histidine 40～60mg, L-cystine 50～70mg, L-methionine 30～50mg, l-glutamine 600～800mg, L-lysine 100～200mg, glycine 20～50mg, L-isoleucine 70～100mg, L-serine 40～100mg, L-leucine 80～150mg, L-tryptophan 10～20mg, L-tyrosine 80～150mg, L-valine 80～150mg, L-threonine 100～200mg, Choline Chloride 2～8mg, Cobastab
20.5～2.5mg, pantothenic acid 2～8mg, folic acid 3～10mg, pyridoxal 3～10mg, vitamin PP 5～10mg, glucose 4～10g, adenosine triphosphate 3～5g, adenosine 2～10g, plasma albumin 20～50g, Dextran-20～50g, red blood cell 50～100g, Verapamil 1～5mg, dexamethasone 4～10mg, glutathione 4～10mg, allopurinol 4～10mg and UTI 25,000～40,000u/kg.
3, preservation liquid as claimed in claim 1 is characterized in that every liter is preserved each component that contains following content in the liquid: NaCl 5.3～6.3g, KCl 0.31～0.50g, NaH
2PO
4H
2O 110～145mg, MgSO
458～80mg, NaHCO
34.1～4.9g, L-arginine 81～85mg, histidine 48～58mg, L-cystine 51～65mg, L-methionine 34～47mg, l-glutamine 612～700mg, L-lysine 112～154mg, glycine 28～43mg, L-isoleucine 71～92mg, L-serine 41～91mg, L-leucine 82～131mg, L-tryptophan 13～19mg, L-tyrosine 85～143mg, L-valine 86～125mg, L-threonine 133～159mg, Choline Chloride 3～5mg, Cobastab
20.9～2.3mg, pantothenic acid 3～4mg, folic acid 4～9mg, pyridoxal 4～9mg, vitamin PP 7～8mg, glucose 4.6～9.9g, adenosine triphosphate 3.4～4.9g, adenosine 3～9g, plasma albumin 24～48g, D-40 28～43g, red blood cell 57～71g, Verapamil 1～5mg, dexamethasone 6～7mg, glutathione 6～7mg, allopurinol 4～9mg and UTI 25,000～40,000u/kg.
4, preservation liquid as claimed in claim 1 is characterized in that preserving in the liquid for every liter and also contains soluble TNF-α 30-300ug/L and/or solubility IL-I 30-300ug/L.
5, preservation liquid as claimed in claim 4 is characterized in that preserving liquid for every liter is made up of following each component: NaCl 5.3g, KCl 310mg, NaH
2PO
4H
2O 110mg, MgSO
468mg, NaHCO
34.1g, L-arginine 82mg, histidine 49mg, L-cystine 51mg, L-methionine 47mg, l-glutamine 700mg, L-lysine 112mg, glycine 43mg, L-isoleucine 71mg, L-serine 41mg, L-leucine 131mg, L-tryptophan 13mg, L-tyrosine 143mg, L-valine 86mg, L-threonine 133mg, Choline Chloride 5mg, Cobastab
22.3mg, pantothenic acid 4mg, folic acid 4mg, pyridoxal 4mg, vitamin PP 8mg, glucose 9500mg, adenosine triphosphate 4.9g, adenosine 9g, plasma albumin 46g, D-40 28g, red blood cell 710g, Verapamil 3mg, dexamethasone 6mg, glutathione 6mg, allopurinol 4mg, UTI 25000u/kg, soluble TNF-α 30ug/L, solubility IL-I 30ug/L, surplus is a deionized water.
6, preservation liquid as claimed in claim 4 is characterized in that preserving liquid for every liter is made up of following each component: NaCl 6.3g, KCl 450mg, NaH
2PO
4H
2O 145mg, MgSO
458mg, NaHCO
34.9g, L-arginine 81mg, histidine 48mg, L-cystine 63mg, L-methionine 34mg, l-glutamine 689mg, L-lysine 154mg, glycine 42mg, L-isoleucine 92mg, L-serine 43mg, L-leucine 910mg, L-tryptophan 17mg, L-tyrosine 85mg, L-valine 125mg, L-threonine 135mg, Choline Chloride 3mg, Cobastab
21.8mg, pantothenic acid 3mg, folic acid 9mg, pyridoxal 5mg, vitamin PP 7mg, glucose 9900mg, adenosine triphosphate 3.4g, adenosine 3g, plasma albumin 24g, D-40 43g, red blood cell 65g, Verapamil 5mg, dexamethasone 6mg, glutathione 7mg, allopurinol 9mg, UTI 30000u/kg, soluble T NE-α 200ug/L, solubility IL-I 200ug/L, surplus is a deionized water.
7, preservation liquid as claimed in claim 4 is characterized in that preserving liquid for every liter is made up of following each component: NaCl 5.3g, KCl 500mg, NaH
2PO
4H
2O 127mg, MgSO
480mg, NaHCO
34.4g, L-arginine 85mg, histidine 58mg, L-cystine 65mg, L-methionine 39mg, l-glutamine 612mg, L-lysine 151mg, glycine 28mg, L-isoleucine 89mg, L-serine 91mg, L-leucine 82mg, L-tryptophan 19mg, L-tyrosine 98mg, L-valine 97mg, L-threonine 159mg, Choline Chloride 3mg, Cobastab
20.9mg, pantothenic acid 4mg, folic acid 5mg, pyridoxal 9mg, vitamin PP 7mg, glucose 4600mg, adenosine triphosphate 4.8g, adenosine 5g, plasma albumin 48g, D-40 32g, red blood cell 57g, Verapamil 1mg, dexamethasone 7mg, glutathione 6mg, allopurinol 7mg, UTI 40000u/kg, soluble TNF-α 300ug/L, solubility IL-I 300ug/L, surplus is a deionized water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810036928XA CN101569302A (en) | 2008-04-30 | 2008-04-30 | In-vitro liver perfusion preservation liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810036928XA CN101569302A (en) | 2008-04-30 | 2008-04-30 | In-vitro liver perfusion preservation liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101569302A true CN101569302A (en) | 2009-11-04 |
Family
ID=41228897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810036928XA Pending CN101569302A (en) | 2008-04-30 | 2008-04-30 | In-vitro liver perfusion preservation liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101569302A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897948A (en) * | 2010-07-16 | 2010-12-01 | 浙江大学 | Application of S-nitroso glutathione |
| CN104996396A (en) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | In-vitro liver perfusion preservation solution |
| CN106035316A (en) * | 2016-04-25 | 2016-10-26 | 浙江大学 | Improved Celsior preservation solution for donor heart, and preparation method and application thereof |
| CN109511650A (en) * | 2018-11-21 | 2019-03-26 | 嘉兴莱普晟医疗科技有限公司 | A kind of room temperature machine perfusion liquid that can expand for liver source |
| CN109769797A (en) * | 2017-11-13 | 2019-05-21 | 合肥华琪生物工程有限公司 | A kind of organ preservative fluid |
| CN112273373A (en) * | 2020-10-29 | 2021-01-29 | 无锡市人民医院 | Isolated lung mechanical perfusion liquid and preparation method and application thereof |
| CN112790189A (en) * | 2021-03-10 | 2021-05-14 | 四川大学华西医院 | Organ perfusion and preservation solution and application thereof |
| CN113453548A (en) * | 2019-02-14 | 2021-09-28 | 北哥罗夫投资公司 | Composition for maintaining viability of living and static biological material, method of manufacture and use thereof |
| CN114831108A (en) * | 2022-05-20 | 2022-08-02 | 杭州联川生物技术股份有限公司 | Fresh tissue preservation solution and preparation method and application thereof |
| CN115777692A (en) * | 2022-11-22 | 2023-03-14 | 武汉大学 | Normal-temperature mechanical perfusion liquid for heart death donor kidney and application thereof |
-
2008
- 2008-04-30 CN CNA200810036928XA patent/CN101569302A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897948B (en) * | 2010-07-16 | 2013-03-13 | 浙江大学 | Application of S-nitroso glutathione |
| CN101897948A (en) * | 2010-07-16 | 2010-12-01 | 浙江大学 | Application of S-nitroso glutathione |
| CN104996396A (en) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | In-vitro liver perfusion preservation solution |
| CN104996396B (en) * | 2015-07-27 | 2016-10-05 | 中山大学附属第一医院 | In-vitro liver perfusion preservation solution |
| CN106035316A (en) * | 2016-04-25 | 2016-10-26 | 浙江大学 | Improved Celsior preservation solution for donor heart, and preparation method and application thereof |
| CN106035316B (en) * | 2016-04-25 | 2018-07-31 | 浙江大学 | A kind of Celsior of improvement preserves liquid and preparation method thereof for the heart |
| CN109769797A (en) * | 2017-11-13 | 2019-05-21 | 合肥华琪生物工程有限公司 | A kind of organ preservative fluid |
| CN109511650A (en) * | 2018-11-21 | 2019-03-26 | 嘉兴莱普晟医疗科技有限公司 | A kind of room temperature machine perfusion liquid that can expand for liver source |
| CN109511650B (en) * | 2018-11-21 | 2021-06-15 | 嘉兴莱普晟医疗科技有限公司 | Normal-temperature mechanical perfusate capable of enlarging liver supply source |
| CN113453548A (en) * | 2019-02-14 | 2021-09-28 | 北哥罗夫投资公司 | Composition for maintaining viability of living and static biological material, method of manufacture and use thereof |
| EP3923719A4 (en) * | 2019-02-14 | 2022-11-30 | North Grove Investments, Inc. | Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof |
| CN112273373A (en) * | 2020-10-29 | 2021-01-29 | 无锡市人民医院 | Isolated lung mechanical perfusion liquid and preparation method and application thereof |
| CN112273373B (en) * | 2020-10-29 | 2022-06-07 | 无锡市人民医院 | Isolated lung mechanical perfusion liquid and preparation method and application thereof |
| CN112790189B (en) * | 2021-03-10 | 2022-04-22 | 四川大学华西医院 | Organ perfusion and preservation solution and application thereof |
| CN112790189A (en) * | 2021-03-10 | 2021-05-14 | 四川大学华西医院 | Organ perfusion and preservation solution and application thereof |
| CN114831108A (en) * | 2022-05-20 | 2022-08-02 | 杭州联川生物技术股份有限公司 | Fresh tissue preservation solution and preparation method and application thereof |
| CN115777692A (en) * | 2022-11-22 | 2023-03-14 | 武汉大学 | Normal-temperature mechanical perfusion liquid for heart death donor kidney and application thereof |
| CN115777692B (en) * | 2022-11-22 | 2024-05-10 | 武汉大学 | Normal-temperature mechanical perfusate for heart death donor kidney and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101569302A (en) | In-vitro liver perfusion preservation liquid | |
| US7005253B2 (en) | Cold storage solution for organ and biological tissue preservation | |
| Szabó et al. | Cardioprotective effects of hydrogen sulfide | |
| CN104996396B (en) | In-vitro liver perfusion preservation solution | |
| JP2002516254A (en) | Cryopreservation of human erythrocytes | |
| WO2015002729A2 (en) | Cell stabilization | |
| Taylor | Biology of cell survival in the cold: the basis for biopreservation of tissues and organs | |
| CN100382688C (en) | Normal temperature and sub-normal temperature in vitro heart preserving perfusate | |
| CN114585255A (en) | Cryopreservation liquid for stem cells | |
| Kahn et al. | Comprehensive review on Custodiol-N (HTK-N) and its molecular side of action for organ preservation | |
| GB2249937A (en) | Solutions for the perfusion, preservation and reperfusion of organs | |
| Ramella et al. | Evaluation of a high sodium-low potassium cold-storage solution by the isolated perfused rat kidney technique | |
| US7014990B2 (en) | Machine perfusion solution for organ and biological tissue preservation | |
| US8563233B2 (en) | Blood substitute solution | |
| RU2450515C1 (en) | Preserving agent for donor cornea | |
| CN105532646A (en) | Liver cell preserving fluid and preparation method and application | |
| Michel et al. | Evaluation of a new preservative solution for cardiac graft during hypothermia | |
| CN104202972A (en) | Organ storage solution containing (hydroxy)ectoine | |
| McAnulty et al. | Comparison of the effects of adenine-ribose with adenosine for maintenance of ATP concentrations in 5-day hypothermically perfused dog kidneys | |
| Mohara et al. | The effect of Celsior solution on 12-hour cardiac preservation in comparison with University of Wisconsin solution | |
| CN113383768B (en) | Hepatocyte freezing solution and preparation method and application thereof | |
| CA2609776C (en) | Preservation solution for organs and biological tissues | |
| KR100304594B1 (en) | Composition for the Preservation of Organs and Blood Cells | |
| WO2024116978A1 (en) | Cold storage solution for stem cells | |
| RU2438698C1 (en) | Water-soluble composition, possessive properties of cardio-protector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091104 |